{"schema_version":"secwatch.filing_event.v1","accession":"0001628280-23-022266","form_type":"8-K","ticker":"XFOR","cik":"0001501697","company_name":"X4 Pharmaceuticals, Inc","filed_at":"2023-06-15T23:59:59+00:00","discovered_at":"2026-05-14T18:03:39.091827+00:00","generated_at":"2026-06-14T00:05:10.913751+00:00","sec_items":["5.07"],"event_type":"other","sentiment":"neutral","materiality_score":0.1,"calibrated_materiality_score":0.1,"confidence":"high","headline":"X4 Pharmaceuticals stockholders elect three directors and approve all proposals at 2023 annual meeting","bullets":["Elected Gary J. Bridger, Francoise de Craecker, and Murray W. Stewart as directors for three-year terms.","Ratified PricewaterhouseCoopers LLP as independent auditor for FY2023 with 94.3M votes for.","Advisory vote on named executive officer compensation approved with 59.3M for vs 8.0M against.","Stockholders preferred a one-year frequency for future say-on-pay votes; board adopted annual votes.","Approved Amended and Restated 2017 Employee Stock Purchase Plan with 66.7M votes for."],"urls":{"canonical":"https://secwatch.observer/filing/0001628280-23-022266","json":"https://secwatch.observer/filing/0001628280-23-022266.json","markdown":"https://secwatch.observer/filing/0001628280-23-022266.md","text":"https://secwatch.observer/filing/0001628280-23-022266.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1501697/000162828023022266/0001628280-23-022266-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1501697/000162828023022266/xfor-20230613.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-14T00:05:10.913751+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"50a782245681bea37b93366b07633e0cc0b3a014","claim":"X4 Pharmaceuticals, Inc shareholders approved Advisory Vote on the Compensation of the Named Executive Officers at the 2023-06-13 meeting.","evidence_excerpt":"The votes cast were as follows: For Against Abstain Broker Non-Votes 59,263,769 7,988,869 175,031 26,939,489","evidence_source":"SEC 8-K Item 5.07","evidence_url":"https://www.sec.gov/Archives/edgar/data/1501697/000162828023022266/0001628280-23-022266-index.htm","confidence":1.0,"family_label":"Shareholder Votes","details":[{"label":"Proposal","value":"say on pay"},{"label":"Outcome","value":"passed"},{"label":"Meeting","value":"2023-06-13"}],"fact_type":"shareholder_vote"},{"claim_id":"71ef4cba7947f781d712f66e8f2b77a072cf8421","claim":"X4 Pharmaceuticals, Inc shareholders approved Ratification of the Selection of Independent Registered Public Accounting Firm at the 2023-06-13 meeting.","evidence_excerpt":"The votes cast were as follows: For Against Abstain Broker Non-Votes 94,283,872 71,919 11,367 —","evidence_source":"SEC 8-K Item 5.07","evidence_url":"https://www.sec.gov/Archives/edgar/data/1501697/000162828023022266/0001628280-23-022266-index.htm","confidence":1.0,"family_label":"Shareholder Votes","details":[{"label":"Proposal","value":"auditor ratification"},{"label":"Outcome","value":"passed"},{"label":"Meeting","value":"2023-06-13"}],"fact_type":"shareholder_vote"},{"claim_id":"781c430fa000b7f9e9454a6b9ad315176b873f14","claim":"X4 Pharmaceuticals, Inc shareholders approved Approval of the Company's Amended and Restated 2017 Employee Stock Purchase Plan at the 2023-06-13 meeting.","evidence_excerpt":"The votes cast were as follows: For Against Abstain Broker Non-Votes 66,701,613 641,702 84,354 26,939,489","evidence_source":"SEC 8-K Item 5.07","evidence_url":"https://www.sec.gov/Archives/edgar/data/1501697/000162828023022266/0001628280-23-022266-index.htm","confidence":1.0,"family_label":"Shareholder Votes","details":[{"label":"Proposal","value":"equity plan"},{"label":"Outcome","value":"passed"},{"label":"Meeting","value":"2023-06-13"}],"fact_type":"shareholder_vote"},{"claim_id":"9542adb1c05d199e1ed25c784d31f5272f97c116","claim":"X4 Pharmaceuticals, Inc shareholders approved Election of Directors at the 2023-06-13 meeting.","evidence_excerpt":"The votes cast were as follows: Nominees For Withheld Broker Non-Votes Gary J. Bridger, Ph.D. 60,120,050 7,307,619 26,939,489 Francoise de Craecker 60,283,484 7,144,185 26,939,489 Murray W. Stewart, M.D. 60,138,639 7,289,030 26,939,489","evidence_source":"SEC 8-K Item 5.07","evidence_url":"https://www.sec.gov/Archives/edgar/data/1501697/000162828023022266/0001628280-23-022266-index.htm","confidence":1.0,"family_label":"Shareholder Votes","details":[{"label":"Proposal","value":"director election"},{"label":"Outcome","value":"passed"},{"label":"Meeting","value":"2023-06-13"}],"fact_type":"shareholder_vote"},{"claim_id":"b45d2a06495ea1a62cd0009ee25b5291b19b9d79","claim":"X4 Pharmaceuticals, Inc shareholders approved Advisory Vote on the Frequency of Future Advisory Votes on Executive Compensation at the 2023-06-13 meeting.","evidence_excerpt":"The votes cast were as follows: 1 Year 2 Years 3 Years Abstain 60,811,809 6,157,200 396,956 61,704","evidence_source":"SEC 8-K Item 5.07","evidence_url":"https://www.sec.gov/Archives/edgar/data/1501697/000162828023022266/0001628280-23-022266-index.htm","confidence":1.0,"family_label":"Shareholder Votes","details":[{"label":"Proposal","value":"say on pay frequency"},{"label":"Outcome","value":"passed"},{"label":"Meeting","value":"2023-06-13"}],"fact_type":"shareholder_vote"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}